Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Vilstrup

Showing results (161-170 of 167) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 167 results.
Acta Oncologica (Stockholm, Sweden)|May 7, 2011
Feasibility of FDG-PET/CT imaging during concurrent chemo-radiotherapy in patients with locally advanced pancreatic cancerJon K Bjerregaard, Barbara M Fischer, Mie H Vilstrup, et al.
Pediatric Obesity|July 31, 2014
The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese childrenK Kazankov, H J Møller, A Lange, et al.
Alimentary Pharmacology & Therapeutics|April 11, 2016
The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosisT D Sandahl, R McGrail, H J Møller, et al.
World Journal of Surgery|February 5, 2000
Postoperative hepatic catabolic stress response in patients with cirrhosis and chronic hepatitisS B Lausten, T El-Sefi, I Marwan, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 6, 2013
Delayed sodium 18F-fluoride PET/CT imaging does not improve quantification of vascular calcification metabolism: results from the CAMONA studyBjörn A Blomberg, Anders Thomassen, Richard A P Takx, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 25, 2025
Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [<sup>18</sup>F]PSMA-1007 PET/CT and [<sup>18</sup>F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient ManagementKaren M Buch-Olsen, Mie H Vilstrup, Steinbjørn Hansen, et al.
European Urology Open Science|June 8, 2026
Progression-free Survival Following Primary Staging with [<sup>18</sup>F]PSMA-1007-PET/ceCT Versus Na[<sup>18</sup>F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled TrialKaren M Buch-Olsen, Steinbjørn Hansen, Mie H Vilstrup, et al.
Pageof 17

Showing results (161-170 of 167) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 167 results.
Acta Oncologica (Stockholm, Sweden)|May 7, 2011
Feasibility of FDG-PET/CT imaging during concurrent chemo-radiotherapy in patients with locally advanced pancreatic cancerJon K Bjerregaard, Barbara M Fischer, Mie H Vilstrup, et al.
Pediatric Obesity|July 31, 2014
The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese childrenK Kazankov, H J Møller, A Lange, et al.
Alimentary Pharmacology & Therapeutics|April 11, 2016
The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosisT D Sandahl, R McGrail, H J Møller, et al.
World Journal of Surgery|February 5, 2000
Postoperative hepatic catabolic stress response in patients with cirrhosis and chronic hepatitisS B Lausten, T El-Sefi, I Marwan, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 6, 2013
Delayed sodium 18F-fluoride PET/CT imaging does not improve quantification of vascular calcification metabolism: results from the CAMONA studyBjörn A Blomberg, Anders Thomassen, Richard A P Takx, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 25, 2025
Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [<sup>18</sup>F]PSMA-1007 PET/CT and [<sup>18</sup>F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient ManagementKaren M Buch-Olsen, Mie H Vilstrup, Steinbjørn Hansen, et al.
European Urology Open Science|June 8, 2026
Progression-free Survival Following Primary Staging with [<sup>18</sup>F]PSMA-1007-PET/ceCT Versus Na[<sup>18</sup>F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled TrialKaren M Buch-Olsen, Steinbjørn Hansen, Mie H Vilstrup, et al.
Pageof 17